Literature DB >> 18545145

Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis.

Darryl A Oble1, Mari Mino-Kenudson, Jeffrey Goldsmith, F Stephen Hodi, Rania M Seliem, Glenn Dranoff, Martin Mihm, Robert Hasserjian, Gregory Y Lauwers.   

Abstract

Monoclonal antibodies (mAbs) against the cytotoxic T lymphocyte antigen-4 (CTLA-4) molecule are used as an adjuvant to experimental tumor immunization protocols in the treatment of malignant melanomas and ovarian cancers. Aside from noted early therapeutic successes, a spectrum of adverse effects, including severe gastroenteritis, has been reported. We report herein our observations of 5 patients who developed severe gastrointestinal toxicity affecting the gastric, small intestinal, and colonic mucosa. The endoscopic findings were variable, ranging from normal to diffusely erythematous and ulcerated mucosa. The constant histologic findings included a lymphoplasmacytic expansion of the lamina propria with increase in intraepithelial lymphocytes. Increased epithelial apoptosis was also a distinctive feature. Cryptitis and glandular inflammation were observed in the colon, ileum, and stomach, whereas villous blunting was present in the ileal and duodenal mucosa. Immunohistochemical analysis revealed a marked increase of all T-cell subsets (CD3+, CD4+, and CD8+) and of CD4CD25 regulatory T cells. We conclude that the panenteritis associated with injection of alpha-CTLA-4 mAbs demonstrates histology resembling autoimmune enteropathy. Furthermore, although the pathogenesis of immune dysregulation after the infusion of alpha-CTLA-4 mAbs remains unclear, we suspect that the increased number of regulatory T cells in the gastrointestinal mucosa may play a role in the pathogenicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18545145     DOI: 10.1097/PAS.0b013e31817150e3

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  31 in total

Review 1.  Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.

Authors:  Xiang-Yang Wang; Daming Zuo; Devanand Sarkar; Paul B Fisher
Journal:  Expert Opin Pharmacother       Date:  2011-12       Impact factor: 3.889

Review 2.  [The pathology of adverse events with immune checkpoint inhibitors].

Authors:  V H Koelzer; K Glatz; L Bubendorf; A Weber; A Gaspert; G Cathomas; A Lugli; A Zippelius; W Kempf; K D Mertz
Journal:  Pathologe       Date:  2017-05       Impact factor: 1.011

Review 3.  Immune checkpoint inhibitor colitis: the flip side of the wonder drugs.

Authors:  Naziheh Assarzadegan; Elizabeth Montgomery; Robert A Anders
Journal:  Virchows Arch       Date:  2017-11-15       Impact factor: 4.064

4.  Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis.

Authors:  B L Adler; M K Pezhouh; A Kim; L Luan; Q Zhu; F Gani; M Yarchoan; J Chen; L Voltaggio; A Parian; M Lazarev; G Y Lauwers; T M Pawlik; E A Montgomery; E Jaffee; D T Le; J M Taube; R A Anders
Journal:  J Intern Med       Date:  2018-03-24       Impact factor: 8.989

5.  Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors.

Authors:  Hajir Ibraheim; Esperanza Perucha; Nick Powell
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

Review 6.  Toxicities of Immunotherapy for the Practitioner.

Authors:  Jeffrey S Weber; James C Yang; Michael B Atkins; Mary L Disis
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

Review 7.  Pathology of non-Helicobacter pylori gastritis: extending the histopathologic horizons.

Authors:  Gregory Y Lauwers; Hiroshi Fujita; Koji Nagata; Michio Shimizu
Journal:  J Gastroenterol       Date:  2009-12-05       Impact factor: 7.527

8.  OsmoPrep-associated Gastritis: A Histopathologic Mimic of Iron Pill Gastritis and Mucosal Calcinosis.

Authors:  Karen Matsukuma; Dorina Gui; Kristin A Olson; Sooraj Tejaswi; Erica F Clayton; Anne Thai
Journal:  Am J Surg Pathol       Date:  2016-11       Impact factor: 6.394

Review 9.  Ipilimumab and its toxicities: a multidisciplinary approach.

Authors:  Leslie A Fecher; Sanjiv S Agarwala; F Stephen Hodi; Jeffrey S Weber
Journal:  Oncologist       Date:  2013-06-17

10.  Ipilimumab-induced perforating colitis.

Authors:  Kisha A Mitchell; Harriet Kluger; Mario Sznol; Douglas J Hartman
Journal:  J Clin Gastroenterol       Date:  2013-10       Impact factor: 3.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.